News & Events

• March 1, 2016
  

  Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations

• February 26, 2016
  

  Toward an Evidence-Based Nonclinical Road Map for Evaluating the Efficacy of New Tuberculosis (TB) Drug Regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious Diseases In Vivo Pharmacology Workshop for TB Drug Development

  Nuermberger E, Sizemore C, Romero K, Hanna D. Toward an Evidence-Based Nonclinical Road Map for Evaluating the Efficacy of New Tuberculosis (TB) Drug Regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious Diseases In Vivo Pharmacology Workshop for TB Drug Development. Antimicrobial Agents and Chemotherapy. 2016 Feb 26;60(3):1177–82.

• February 20, 2016
  

  Finding Routes to Duchenne Drug Approvals

• December 31, 2015
  

  Evaluation of the Relative Performance of Drug-Induced Skeletal Muscle Injury Biomarkers in Rats

  Burch PM, Hall DG, Walker EG, Bracken W, Giovanelli R, Goldstein R, Higgs RE, King NMP, Lane P, Sauer JM, Michna L, Muniappa N, Pritt ML, Vlasakova K, Watson DE, Wescott D, Zabka TS, Glaab WE. Evaluation of the Relative Performance of Drug-Induced Skeletal Muscle Injury Biomarkers in Rats. Toxicological Sciences. 2015 Dec 31.

• December 30, 2015
  

  Practical considerations for the use of clinical outcome assessments (COAs) in pediatric clinical research with examples from pediatric gastroenterology